CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL — Stella

Home/Acute Lymphoblastic Leukemia, in Relapse/

View on ClinicalTrials.gov

Recruiting

Back to Acute Lymphoblastic Leukemia, in Relapse trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

China

The First Affiliated Hospital of Nanchang University;, Nanchang, Jiangxi

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality

Key details

Phase

Early testing

Sponsor

Rong Tao

Collaborators

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Enrollment target

~48 participants

Started

May 2024

Primary completion

October 2026

Age range

18 Years and older

Last updated June 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.